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 INTRODUCTION
Hyperuricemia is commonly found in the general population, with 
a prevalence of about 20 to 25% in adult men and slightly lower 
prevalence in pre-menopausal women. In both genders, incidence 
increases with age1. The prevalence of chronic kidney disease (CKD) 
has been increasing in the past few years, with its morbidity and 
mortality not only related to the end-stage renal disease (ESRD), but 
also with cardiovascular disease. As such, every effort must be made 
to slow its progression.
Emerging evidence suggests that the relationship between hyper-
uricemia and CKD is more than just a marker of renal dysfunction, playing 
a much more important role in its pathogenesis and progression, and 
cardiovascular morbidity-mortality as well. If that association proves to 
be true, the next question would be when to treat hyperuricemia, and 
which drugs should be used. Allopurinol has been used for a long time, 
but febuxostat has been showing growing evidence not only regarding 
the control of hyperuricemia, but also on slowing CKD progression.
In this review, we will try to answer those questions, while describ-
ing the most recent evidence on hyperuricemia as a risk factor for 
CKD and its management in those patients.
 BIOLOGICAL BASES
 Uric Acid Homeostasis
Uric acid (UA) is a compound endogenously produced by the purine 
metabolism. These purines, generated in the liver (either from dietary 
or from endogenous synthesis), are first metabolized into guanine 
and hypoxanthine, and then into xanthine, which is oxidized into UA 
by xanthine oxidase2. Although the reason is not entirely understood, 
contrary to other mammals, hominids have lost the enzyme uricase, 
responsible for converting UA into a more soluble molecule3,4. As 
such, UA is excreted unmetabolized, mainly by the kidney (about two-
thirds), and about one-third through the intestinal tract5,6. Several 
genes encoding membrane transporters responsible for UA excretion 
have been identified, such as Abcg2 (ATP-binding cassette subfamily 
G membrane 2) in the enterocytes and proximal renal tubular epithe-
lium; and others associated with UA reabsorption in the renal tubule, 
such as URAT1 (urate anion exchanger 1) and GLUT9 (glucose trans-
porter type 9)7.
 Physiological Functions
UA has two main functions in the human body. The first is related 
to its role in the elimination of nitrogenous compounds, such as 
ammonia and urea. The second is derived from its potent antioxidant 
activity, which is so important that more than half of normal human’s 
free-radical scavenging capacity in the serum is related to UA8,9. 
This ability is of great importance to the microvascular endothelium, 
where UA prevents oxidative inactivation of endothelial enzymes, 
maintaining its ability to mediate vascular dilation in situations of 
oxidative stress10.
Apart from its beneficial biological effects, higher levels of UA 
have been linked to a higher risk of cardiovascular disease, with 
several studies describing it as an independent risk predictor of 
cardiovascular mortality10,11. This duality has been named the uric 
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acid paradox3. A possible explanation, derived primarily from animal 
studies, is that UA has different actions depending on the surround-
ing cells and chemical environment12. In addition to the extracellular 
effects related to endothelial cells already described, intracellular 
UA exerts pro-oxidant effects: it reduces nitric oxide inside endo-
thelial cells, stimulates vascular smooth muscle cells proliferation 
and promotes production of reactive oxygen species and insulin 
resistance in adipocytes10.
 DEFINITION OF HYPERURICEMIA
The definition of hyperuricemia is still debated, and there is no 
universal consensus. A practical answer is based on the UA solubility 
point at physiologic temperature and the pH, which is 6.8 mg/dl10. 
However, many clinical trials have been using different cut-offs, with 
levels of UA >7 or 7.5 mg/dl in men and >6 or 6.5 mg/dl in women5. 
In fact, the UA threshold for pathologic level is still controversial, as 
the levels in healthy population are very heterogeneous, and a large 
proportion of individuals with high levels of UA do not develop clinical 
manifestations of gout10.
 PATHOPHYSIOLOGY OF HYPERURICEMIA IN CKD
Hyperuricemia has been conceptually determined by two types 
of causes: overproduction and underexcretion of UA; however, there 
can be a combination of both mechanisms. Hyperuricemia rises in 
parallel with glomerular filtration rate (GFR) decline, and is present 
in about 40% of patients with CKD stages I to III and 70% of patients 
with CKD stage IV or stage V6.
UA may be associated with CKD development and progression 
through several mechanisms, some of them crystal-independent13: 
direct toxicity to the kidney; exacerbation of other risk factors for 
kidney disease, such as hypertension; or by being a marker of the 
severity of other risk factors, including those attributable to or associ-
ated with diabetes and the metabolic syndrome14. Some experimental 
studies suggest that hyperuricemia induces renal injury through renal 
vasoconstriction mediated by endothelial dysfunction, activation of 
the renin-angiotensin system, afferent arteriolopathy, and epithelial-
to-mesenchymal transition in renal tubular cells15. Additionally, hyper-
uricemia increases renin activity, leading to the upregulation of angio-
tensin II and proliferation of vascular smooth muscle cells15. This 
results in vascular wall thickening, which leads to lumen obliteration 
and hypoperfusion of the kidney, with tubulointerstitial inflammation 
and fibrosis, as well as arterial hypertension16. Furthermore, preglo-
merular vasculopathy caused by hyperuricemia disturbs the autoregu-
latory response of afferent arterioles, prompting glomerular hyperten-
sion15. Tubulointerstitial fibrosis can also be a result of a UA induced 
epithelial-to-mesenchymal transition in renal tubular cells17. In fact, 
in animal models, administration of a uricase inhibitor to rats caused 
tubular dilatation, cortex atrophy and glomerulosclerosis18. Recent 
evidence also confirms an important role of UA induced inflammation, 
both by the more known crystal-dependent mechanisms, but also by 
direct effect of soluble urate, through oxidative stress, proinflamma-
tory signaling, autophagy and intracellular immunometabolic 
sensors19.
  ASSOCIATIONS BETWEEN HYPERURICEMIA  
AND CKD
Despite the vast evidence of an association between higher UA 
levels and several risk factors for CKD, there are still conflicting results 
in clinical studies, with several unanswered questions regarding the 
role of UA as a casual, compensatory or coincidental phenomenon in 
these patients.
 Hyperuricemia CKD: risk factor or risk marker?
It has long been known that there is a strong association between 
serum UA (sUA) levels and hypertension. In a meta-analysis regarding 
this association, Grayson et al showed that hyperuricemia causes a 
41% increase in the risk of developing hypertension, with this associa-
tion more pronounced in women and a younger population20. 
Although the mechanism for this association is not well understood, 
it is probably related to UA mediated activation of the renin-angio-
tensin system, suppression of nitric oxide and direct vascular damage 
(especially to the renal afferent arterioles)21.
UA has long been associated with renal disease. At first, based on 
studies that showed an increase in the incidence of hyperuricemia in 
parallel with the decline in GFR, it was considered only a marker of 
CKD, instead of a risk factor causing it3. However, the association 
between hyperuricemia and CKD may not be simply a consequence 
of decrease excretion of UA, and there are several studies confirming 
the association between hyperuricemia and the development and 
progression of CKD. In a community-based cohort with 13,388 patients 
followed for 9 years, baseline sUA levels were associated with increased 
risk for CKD, with odds ratios (OR) of 1.07 (95% confidence interval 
– CI 1.01-1.14) per each increase of 1 mg/dl in sUA, in a GFR-based 
model, even after adjustment for possible confounding parameters14. 
In another prospective study with 21,475 individuals followed for 7 
years, patients with slight to moderate elevation of sUA (7.0 to 8.9 
mg/dl) were associated with a nearly doubled risk for kidney disease 
(OR 1.74, with 95% CI 1.45 to 2.09), and patients with very high sUA 
(≥9.0 mg/dl) were associated with a threefold risk for kidney disease 
(OR 3.12, with 95% confidence interval 2.29 to 4.25)22.
However, not every study regarding this issue confirmed the asso-
ciation between UA and incident of CKD and its progression. In a study 
with 227 patients followed for 7 years, with CKD of non-diabetic etiol-
ogy, there was no relationship between sUA levels and kidney disease 
progression when the analysis was adjusted for baseline kidney function 
parameters23. In the MDRD study (Modification of Diet in Renal Dis-
ease), with 838 patients with CKD stages 3-4 followed for 10 years, the 
results showed a positive association of hyperuricemia with all-cause 
and cardiovascular mortality, but not with kidney failure (HR 1.02, with 
95% CI 0.97 to 1.07)24. Thus, some claim that hyperuricemia is just an 
epiphenomenon of CKD, but not and independent risk factor25.
 Hyperuricemia in dialysis patients
Serum UA levels vary greatly in dialysis patients, whether hemo-
dialysis (HD) or peritoneal dialysis (PD). In HD patients, the mean 
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reported level of UA is 7.7 mg/dL (standard deviation of 1.4)26, whereas 
in PD patients the mean level of UA is 8.5 mg/dL (standard deviation 
of 2.1)27. However, these levels are highly variable between studies, 
and and need careful interpretation, since UA levels in patients receiv-
ing dialysis depend on several factors, such as the dialysis prescription 
or the timing of the sample collection.
In HD, UA clearance is similar to urea28, since UA easily diffuses 
into the dialysis effluent. In an HD session with a standard prescrip-
tion, the single pooled UA removal ration is 60-70% with high-flux 
dialyzers29. UA clearance for PD is 10-20 mL/min, being directly pro-
portional to the dialysate exchange volume and flow rate30, and there 
seems to be no difference between automated and continuous ambu-
latory PD31.
The relationship between UA and mortality in dialysis patients has 
been evaluated in several studies, summarized by Murea and Tucker 
in a recent review10, which included 14 studies of patients on HD, and 
five studies in patients on PD. Regarding patients on HD, nine of the 
fourteen studies found an inverse association between UA and all-
cause mortality. In one of those studies (n= 5827), Latif et al found 
that higher UA level were associated with lower all-cause mortality, 
with an hazard ration of 0.95 per 1 mg/dl higher UA level32. However, 
five of those studies found either no association or a direct association 
between UA and mortality. As for PD, two of those studies found a 
direct association between UA and mortality, while the other three 
studies found none.
There are important differences in the results among those studies, 
which can be a consequence of several biases. However, there seems 
to be an important difference between both dialysis techniques, since 
the inverse association of higher UA levels and lower mortality was 
specific only for HD. Although there is no clear explanation for these 
results, there are some hypotheses suggested. Some advocate that 
higher sUA levels are associated with less mortality because sUA is a 
marker of better nutrition. However, some studies showed that, even 
after adjustment for nutritional parameters, there was still an associa-
tion between sUA and mortality. In one of those studies33, a prospec-
tive study with 261 patients on HD, the authors demonstrated an 
association between higher levels of sUA and a lower hazard ratio for 
hospitalization and cardiovascular and all-cause death, even after 
adjustment for nutritional parameters. Thus, despite the fact that 
hyperuricemia is related to better nutritional status, this does not 
seem to be the explanation for the lower mortality in HD patients. 
Yet, this argument cannot explain the difference found between HD 
and PD patients.
Another explanation for these results relies on the timing of mea-
surement of sUA levels in HD patients. Given that UA is dialysated in 
a similar way to urea, levels will fluctuate greatly between HD sessions, 
and the pre-HD concentration does not reflect the mean levels in 
those patients. Some studies show that after a HD session, sUA levels 
tend to decrease by 64.6%34, which means that, between two ses-
sions, those patients will have sUA between those levels. Thus, a 
patient with normal or low sUA before HD would have a much lower 
weekly time-averaged mean sUA, with levels probably lower than the 
necessary concentration for UA to execute its normal antioxidant func-
tions. Likewise, patients with high sUA levels before HD would have 
near-normal mean sUA levels weekly time-averaged10. Although this 
is an unconfirmed hypothesis, it could explain the protective effects 
of higher pre-HD sUA levels, and the difference between HD and PD 
patients.
 Hyperuricemia in transplant patients
Hyperuricemia is frequent in renal transplant patients, normally 
occurring early in the post-transplant period25. Frequent risk factors 
for hyperuricemia in these patients include the use of calcineurin 
inhibitors (cyclosporine being the most common risk factor for hyper-
uricemia in the post-transplant period35) or diuretics, reduced glo-
merular filtration rate (GFR), obesity, recipient age and pre-existing 
history of hyperuricemia36.
However, the evidence regarding the effects of hyperuricemia on 
renal allograft function and survival is very heterogeneous and incon-
clusive37. Some studies showed an inverse association between hyper-
uricemia and renal allograft function and survival38-40, suggesting a 
role for hyperuricemia as an independent risk factor. However, this 
association is not evident in other studies, which conclude that sUA 
is merely a marker of graft dysfunction41-43.
The evidence regarding treatment of asymptomatic hyperuricemia 
is also controversial. However, lifestyle measures and avoidance of 
cyclosporine and diuretics are acceptable strategies to reduce sUA 
levels36.
 TREATMENT OF HYPERURICEMIA IN CKD
 General principles
As a result of the lack of strong evidence regarding the role of 
hyperuricemia in patients without gout or nephrolithiasis, current 
guidelines do not support the treatment of isolated hyperuricemia 
with urate lowering therapy. However, advice on lifestyle and the 
treatment of associated comorbidities is always advised44.
Despite the limited effect of lifestyle modification on sUA and the 
lack of evidence from RCTs, every patient with hyperuricemia should 
receive appropriate advice on lifestyle recommendations to lower 
sUA. Furthermore, most of these measures are useful in the vast 
majority of the comorbidities that patients with hyperuricemia fre-
quently have45. However, given their limited effect, they should be 
considered an adjunctive, and should not replace pharmacologic treat-
ment, whenever indicated46. Those measures include:
•  Reduce weight and daily exercise, even though the effects are 
only modest (losing 7.7 kg decreases, in average, 1.6 mg/dL in 
sUA)47;
•  Decrease consumption of purine-rich meat and seafood;
•  Reduce energy drinks and soft drinks sweetened with fructose 
corn syrup45;
•  Limit the intake of beer, wine and spirits46;
•  Minimize the use of drugs that increase sUA, such as diuretics, 
beta-blockers or low dose of acetylsalicylic acid3.
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 Urate-lowering agents
There are 3 main classes of urate-lowering agents: uricosuric 
agents, which increase kidney UA excretion; xanthine oxidase inhibi-
tors (allopurinol and febuxostat), which block the conversion of purine 
metabolites to UA; and recombinant uricases, which oxidize UA into 
a highly soluble product48.
 Allopurinol
Allopurinol is a xanthine oxidase inhibitor, and it is metabolized 
into oxypurinol, which is excreted by the kidneys. For this reason, and 
since allopurinol may cause hypersensitive reactions, its dose must 
be reduced in patients with CKD. In patients with an eGFR <60 mL/
min/1.73m2, it is recommended to start at a dose of 50-100 mg/day, 
increasing the dose to 200 or 300 mg/day after 2-5 weeks to achieve 
serum UA levels of <6 mg/dL. It is acceptable to use doses >300 mg/
day, as long as there is proper monitoring of toxicity48. Its main adverse 
events are related to allopurinol hypersensitivity syndrome, character-
ized by skin rash, eosinophilia, hepatitis and fever, a rare but potentially 
life-threatening condition49.
There is generally a scarcity of RCT regarding effects of control of 
hyperuricemia in CKD patients. In a 2013 systematic review of 8 RCT, 
Bose et al compared treatment of hyperuricemia with allopurinol versus 
placebo and its effect on the retardation of CKD50. In 5 of these studies, 
they found no significant differences in eGFR among patients in each 
group. The other 3 trials showed a slight benefit on the allopurinol 
arm, but no significant changes in proteinuria or blood pressure. How-
ever, there was an important heterogeneity in the monitorization of 
kidney function and the follow-up among these studies.
In another meta-analysis which included 19 RCTs, Kanji et al found 
significant benefits with allopurinol therapy in terms of reducing serum 
UA levels, blood pressure control and a slight improvement in eGFR51.
 Febuxostat
Febuxostat is a newer xanthine oxidase inhibitor, with more efficacy 
and specificity than allopurinol for xanthine oxidase52. Its elimination 
is mainly by the liver and bile, and it is less associated with hypersen-
sitivity than allopurinol53. Its main adverse effects include liver function 
abnormalities, diarrhea and rash. It should not be used simultaneously 
with azathioprine or mercaptopurine, since those drugs are metabo-
lized by xanthine oxidase and their levels may increase, causing toxic-
ity54. Regarding its safety in renal disease, it can be used without dose 
reduction in patients with eGFR ≥30 mL/min. However, most of the 
safety studies included only a few patients with CKD stages ≥4, and 
the studies in patients on dialysis are even fewer, which is why the 
FDA has not yet approved febuxostat in that population. Other than 
that, it appears to be well tolerated and efficient. Thus, it should be 
used with dose reduction in patients with CKD stages 4-546,55,56.
In spite of being a newer drug than allopurinol, there are already 
several published studies demonstrating its beneficial effects on renal 
function. In a post-hoc analysis of the FOCUS (Febuxostat Open-label 
Clinical trial of Urate-lowering efficacy and Safety) study, with 116 hyper-
uricemic gout patients receiving febuxostat at different doses (40, 80, 
or 120 mg) for 5 years, there was a clear benefit on renal function, with 
maintenance (or even improvement) in eGFR that was inversely cor-
related with the amount of reduction in sUA, with an expected improve-
ment in eGFR of 1 mL/min for every 1 mg/dL reduction in sUA57.
In the EXCEL (Febuxostat/Allopurinol Comparative Extension Long-
Term) study (n=1086), patients were treated with either febuxostat 
(80 or 120 mg daily) or allopurinol (300 mg daily). The febuxostat 
group showed significant benefits of renal function, with greater reduc-
tions in sUA associated with less decline in renal function (preservation 
of 1.2 mL/min/1.73 m2 for every 1 mg/dL reduction in sUA)58.
However, some studies failed to show beneficial renal outcomes 
with febuxostat. More recently, a randomized trial with 467 patients 
with stage 3 CKD, receiving either placebo of febuxostat, showed no 
significant difference in renal function within the febuxostat, with 
similar mean eGFR slopes between both groups59.
There are several ongoing trials regarding the effects of urate-
lowering therapy with febuxostat, as conclusive evidence is needed.
 Other pharmacological agents
Uricosuric agents include benzbromarone, lesinurad, probenecid 
and sulfinpyrazone. Despite being effective in reducing sUA in patients 
with normal kidney function, their use is limited in CKD patients, being 
contraindicated for stage IV CKD (lesinurad is contraindicated if cre-
atinine clearance <45 mL/min), including dialysis patients46. The evi-
dence regarding their benefit on slowing renal dysfunction is scarce, 
but there are some studies running regarding this issue45. Also, their 
use must be avoided in patients with past history of nephrolithiasis, 
and are contraindicated in patients with uricosuria greater that 700 
to 800 mg/24h46. Further, there are some issues concerning their 
safety, with lesinurad being associated with acute kidney injury when 
used alone (which is the reason it needs to be co-prescribed with a 
xanthine oxidase inhibitor), and benzbromarone being associated with 
hepatotoxicity60.
Other drugs commonly used for other medical indications but with 
uricosuric properties include losartan, fenofibrate, SGLT2 inhibitors, 
vitamin C and high doses of acetylsalicylic acid45,46.
Pegloticase, a recombinant uricase, is approved for use in patients 
with gout that is refractory to oral agents for hyperuricemia. It is 
administered intravenously, and can be used in patients with advanced 
CKD and dialysis patients46. Rasburicase is another recombinant uri-
case which is approved for use in patients with malignancies receiving 
chemotherapy, when tumor lysis syndrome is expected61.
 CONCLUSION
The association between hyperuricemia and CKD has long been 
known. However, although many observational studies have identified 
associations between hyperuricemia and the onset and progression 
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CKD, some have not. Thus, although much evidence points toward a 
role of sUA in the pathogenesis of CKD, the current evidence cannot 
conclude for certain that it is not just a marker of kidney dysfunction.
Regarding treatment of hyperuricemia, and as a consequence of 
the heterogeneous evidence on the role of UA in CKD, there is still no 
indication for treating asymptomatic patients. Although there are 
several observational studies evaluating the effect of urate lowering 
therapy on the development and progression of CKD, the results are 
heterogeneous, much derived from several biases, including the small 
number of patients included in much of them, and the short follow-
up. For more clear and accurate results, large randomized controlled 
trials are needed. Besides that, there are still some doubts on whether 
the renoprotective effects of allopurinol and febuxostat found in some 
studies are related to their effect on sUA levels, or to their xanthine 
oxidase inhibition. Another question yet to be answered is the sUA 
level at which pharmacological therapeutic must be started, and the 
optimal target level to slow CKD progression.
Concluding, although there are already some insights into the 
role of hyperuricemia in CKD, and the potential renoprotective effects 
of urate lowering therapy, the current evidence is still not strong 
enough to make valid conclusions, and well-conducted studies are 
needed.
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